

9 September 2025

## Osteopore announces collaboration with Tan Tock Seng Hospital for the development of a novel implant for avascular necrosis

### Highlights

- Osteopore embarks on a co-development collaboration for a novel implant for the treatment of avascular necrosis (AVN) with Tan Tock Seng Hospital, led by clinical Principal Investigator Dr Michael Yam.
- The collaboration is funded by a SGD 50,000 MedTech grant from NHG Health.
- The total market opportunity of AVN treatment is projected to reach USD 10.2 billion by 2030, at a CAGR of 8.5% between 2023 and 2030<sup>1</sup>.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce a co-development collaboration with Tan Tock Seng Hospital, an anchor hospital of NHG Health, for the development of a novel implant used in the treatment of avascular necrosis (AVN) at the hip joint.

The collaboration is funded by a SGD 50,000 MedTech grant from NHG Health and led by Principal Investigator (PI) Dr Michael Yam Gui Jie, a Consultant from the Department of Orthopaedic Surgery, and Clinical Director of the Medical 3DP Centre at Tan Tock Seng Hospital (TTSH).

---

<sup>1</sup> <https://www.verifiedmarketresearch.com/product/avascular-necrosis-market/>

AVN is a condition where blood supply is interrupted, leading to necrosis of bone tissue. This condition occurs predominantly at the hip joint, although it can happen at other joints as well.

AVN of the hip can cause pain and discomfort. The conditions worsen over time, and without treatment, can result in the collapse of the bone at the hip joint. When that happens, total hip replacement (THR) becomes the most effective treatment. Approximately 10% of AVN cases result in THR. It is reported that there are between 20,000 and 30,000 new cases of AVN in the U.S. each year<sup>2</sup>.

The total market opportunity of AVN treatment is projected to reach USD 10.2 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 8.5% between 2023 and 2030<sup>3</sup>. Growth drivers include: growing prevalence of AVN, increasing awareness of AVN, and earlier diagnosis.

Under the collaboration, Osteopore will work with Dr Yam to design and perform the necessary tests to arrive at a proof-of-concept for a novel implant that enhances outcomes for core decompression in AVN of the hip.

The collaboration runs for a period of 12 months starting September 2025, and ends with potential first-in-human milestones.

**Commenting on the co-development of a novel scaffold to treat AVN, CEO Dr Yujing Lim, said:**

“We are delighted to embark on another important innovation in orthopaedic surgery that has the potential to reduce healthcare costs.

---

<sup>2</sup> <https://www.yalemedicine.org/conditions/avascular-necrosis-of-the-hip>

<sup>3</sup> <https://www.verifiedmarketresearch.com/product/avascular-necrosis-market/>

"This innovation has the potential to expand Osteopore's product offering in orthopaedics and strengthens our collaboration with commercial partners such as DKSH, which distributes for us in Singapore.

"We look forward to the collaboration, and will provide timely updates to the market on the progress of this project", said Dr Lim.

**Commenting on the co-development with Osteopore , Dr Michael Yam, said:**

"AVN has a high prevalence in Asia, yet current treatment options remain limited. This collaboration, enabled by NHG Health's Centre for Medical Technologies and Innovations (CMTi), is an important step towards driving innovation that can create new treatment solutions and enhance the quality of life for patients", said Dr Yam.

**ENDS**

*This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Dr Yujing Lim**

Chief Executive Officer  
Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Mark Leong**

Executive Chairman  
Osteopore Limited

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### About NHG Health

NHG Health is a leading public healthcare provider in Singapore recognised for its quality clinical care and its commitment in enabling healthier lives through preventive health, innovative solutions and person-centred programmes tailored to every life stage. Our integrated health system, which spans primary care, hospitals and national specialty centres, includes Tan Tock Seng Hospital, Khoo Teck Puat Hospital, Woodlands Health, Yishun Community Hospital, NHG Polyclinics, the Institute of Mental Health, National Skin Centre and the National Centre for Infectious Diseases.

Together with academic and industry partners, we advance medical education, research and healthcare innovation in Singapore, addressing areas that are critical to Singapore's population needs. As the Regional Health Manager for Central and North Singapore, NHG Health partners general practices and health and social care agencies to ensure the physical, mental and social well-being of residents in the community. Together, we are committed to building healthier and resilient communities, and Adding Years of Healthy Life to the people we serve.

### About Tan Tock Seng Hospital

Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, is one of Singapore's largest and pioneering multidisciplinary hospitals. Affectionately known as the People's Hospital, TTSH has a dedicated healthcare team of over 11,000, operates more than 2,000 beds, and provides care across more than 60 clinical disciplines. It is home to NHG Health's National Centre for Infectious Diseases (NCID) a 330-bed purpose-built facility designed to strengthen Singapore's capabilities in infectious disease management and prevention.

TTSH anchors HealthCity Novena—Singapore's first integrated healthcare hub, spanning 17 hectares, and as part of NHG Health, TTSH is committed to empowering individuals in Central and North Singapore to lead healthier lives, transforming care through innovation, research and clinical excellence — adding years of healthy life to the community.

### Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.



Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.



For personal use only